AtriCure, Inc. (ATRC) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
AtriCure exhibits strong short-term growth supported by 16% revenue increase in Q3, positive EBITDA growth, cash flow improvement, clinical pipeline advancements, and strong technical breakout despite near-term technical softness.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Cash Conversion ⢠Margin Pressure ATRC has strong liquidity, solid cash generation, and healthy gross margins, but its full-year profitability remains weak due to a heavy cost base, making it a mixed but improving investment case.
Price Behavior
Key Price Behavior Insights: ⢠Support Rebound ⢠Range Bound ⢠Near Resistance Support Level: $27.37â$27.63 Resistance Level: $29.7â$30.0 ATRC has stabilized and rebounded off the low $27s over the last month, but repeated stalls near $29.7â$30.0 keep the setup neutral until it breaks resistance cleanly.
Sentiment & News
Key News Insights: ⢠Scheduled earnings ⢠Routine update ⢠No new catalyst AtriCure scheduled its Q1 2026 earnings release and webcast for May 5, signaling a routine update with no new operational or strategic developments.
AI Summary
ATRC now looks less like a âgrowth-at-any-costâ story and more like a potential operating-leverage inflection, with strong gross margins, recent positive earnings/FCF, and solid liquidity suggesting profitability can scale if execution holds, but the key risk is that weak segments like minimally invasive ablation and hybrid AF could keep revenue growth from converting into durable returns.
Description
AtriCure develops, manufactures and sells surgical systems and devices used to ablate cardiac tissue and intercostal nerves, serving hospitals and cardiac centers in the United States and internationally. Its portfolio includes radiofrequency and cryoablation systems, epicardial appendage occlusion and suture-based closure solutions, and a range of supporting instruments and disposables for electrophysiology and cardiac surgery. The company distributes products through a mix of independent distributors and direct sales teams and is headquartered in Mason, Ohio; it was incorporated in 2000.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 12 | Jan 19 | ATRC | AtriCure, Inc. | AtriCure exhibits strong short-term growth supported by 16% revenue increase in Q3, positive EBITDA growth, cash flow improvement, clinical pipeline advancements, and strong technical breakout despite near-term technical softness. | Closed | +3.8% |